OTCMKTS:TKPYY - Takeda Pharmaceutical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$20.9550 -0.21 (-0.97 %)
(As of 09/21/2018 04:00 PM ET)
Previous Close$21.16
Today's Range$20.91 - $21.08
52-Week Range$18.93 - $31.29
Volume245,036 shs
Average Volume367,924 shs
Market Capitalization$32.78 billion
P/E Ratio17.20
Dividend Yield2.87%
Beta0.5
Takeda Pharmaceutical logoTakeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. The company operates in three segments: Prescription Drug, Consumer Healthcare, and Other. It offers prescription, OTC, and quasi-drugs; and reagents in various therapeutic areas, including oncology, gastroenterology, central nervous system (CNS), vaccines, and others. The company is also involved in clinical diagnostics, chemical products, and other businesses. Takeda Pharmaceutical Company Limited has a research collaboration with Shattuck Labs, Inc. to explore and develop checkpoint fusion proteins that have the potential to become immunotherapies; and a collaboration alliance with Stanford University. It also has collaboration agreements with Samsung Bioepis Co., Ltd. to jointly fund and co-develop various novel biologic therapies in unmet disease areas; AstraZeneca PLC to develop and commercialize MEDI1341, an alpha synuclein antibody for the treatment of Parkinson's disease; Noile-Immune Biotech Inc. for the research and development of cancer immunotherapy; HitGen Ltd for the DNA-encoded library based drug discovery research; Montreal Neurological Institute to discover and develop treatments for amyotrophic lateral sclerosis; Denali Therapeutics to develop and commercialize therapeutic product candidates for neurodegenerative diseases; Fujifilm to develop regenerative medicine product for heart patients; and Wave Life Sciences Ltd. to discover, develop, and commercialize nucleic acid therapies for disorders of CNS, as well as Drugs for Neglected Diseases initiative. In addition, the company has a licensing agreement with Fimecs, Inc. for the development of novel immuno-oncology therapies; and a clinical collaboration with Nektar Therapeutics to evaluate the combination of NKTR-214 and TAK-659. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

Receive TKPYY News and Ratings via Email

Sign-up to receive the latest news and ratings for TKPYY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:TKPYY
CUSIPN/A
Phone816-6204-2111

Debt

Debt-to-Equity Ratio0.47
Current Ratio1.44
Quick Ratio1.19

Price-To-Earnings

Trailing P/E Ratio17.20
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.99 billion
Price / Sales2.05
Cash Flow$2.0053 per share
Price / Cash10.45
Book Value$11.61 per share
Price / Book1.80

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$1.69 billion
Net Margins6.69%
Return on Equity10.04%
Return on Assets4.84%

Miscellaneous

Employees27,230
Outstanding Shares1,562,360,000
Market Cap$32.78 billion

Takeda Pharmaceutical (OTCMKTS:TKPYY) Frequently Asked Questions

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the OTCMKTS under the ticker symbol "TKPYY."

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Co Ltd (OTCMKTS:TKPYY) released its quarterly earnings results on Tuesday, July, 31st. The company reported $0.69 earnings per share (EPS) for the quarter. The business had revenue of $4.12 billion for the quarter. Takeda Pharmaceutical had a net margin of 6.69% and a return on equity of 10.04%. View Takeda Pharmaceutical's Earnings History.

When is Takeda Pharmaceutical's next earnings date?

Takeda Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for Takeda Pharmaceutical.

Who are some of Takeda Pharmaceutical's key competitors?

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the folowing people:
  • Mr. Christophe Weber, Presidednt, CEO & Representative Director (Age 52)
  • Mr. Andrew S. Plump M.D., Ph.D., Chief Medical & Scientific Officer and Director
  • Dr. Seigo Izumo M.D., Chair of Management Board
  • Mr. Costa Saroukos, Chief Financial Officer
  • Mr. Haruhiko Hirate, Member of Management Board and Corp. Communications & Public Affairs Officer

Has Takeda Pharmaceutical been receiving favorable news coverage?

News headlines about TKPYY stock have trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Takeda Pharmaceutical earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned news stories about the company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Takeda Pharmaceutical.

How do I buy shares of Takeda Pharmaceutical?

Shares of TKPYY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Takeda Pharmaceutical's stock price today?

One share of TKPYY stock can currently be purchased for approximately $20.9550.

How big of a company is Takeda Pharmaceutical?

Takeda Pharmaceutical has a market capitalization of $32.78 billion and generates $15.99 billion in revenue each year. Takeda Pharmaceutical employs 27,230 workers across the globe.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 Doshomachi 4-chome Chuo-ku, Osaka M0, 540-8645. The company can be reached via phone at 816-6204-2111 or via email at [email protected]


MarketBeat Community Rating for Takeda Pharmaceutical (OTCMKTS TKPYY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  195
MarketBeat's community ratings are surveys of what our community members think about Takeda Pharmaceutical and other stocks. Vote "Outperform" if you believe TKPYY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TKPYY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel